Sanofi-aventis announced that the European Commission has cleared sanofi-aventis’ proposed acquistion of Genzyme corporation unconditionally under EU merger control rules. Sanofi-aventis welcomes this decision, which is a requisite step in satisfaction of the condition to the tender offer relating to antitrust approvals.
The offer remains subject to the other conditions described in the offer to purchase filled with the U.S. Securities and Exchance Commission on October 4, 2010, as amended to date.
